Medexus Appoints Michael Pine as Senior Vice President of Business Development and Strategy
September 25 2020 - 7:30AM
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”)
(TSXV: MDP, OTCQX:
MEDXF), today
announced the appointment of Michael Pine as Senior Vice President
of Business Development and Strategy, effective September 21, 2020.
Mr. Pine’s responsibilities include developing Medexus’ product
portfolio in both the U.S. and Canada.
Mr. Pine is an experienced pharmaceutical
industry executive and business leader with a diverse background in
both large and small pharmaceutical companies that includes
functions in: business development & licensing, M&A,
investment banking, business strategy, product marketing, US
managed markets, and operations. Most recently, Mr. Pine served as
SVP, Business Development & Licensing at Lupin Pharmaceuticals,
where he led Lupin's efforts to expand their over $2 billion
revenue base further into branded and specialty products with a
focus on the North American markets. Prior to that role, Mr. Pine
was the VP, Head of Corporate Development & Licensing at Aralez
Pharmaceuticals. Mr. Pine also served in a variety of senior roles
at companies such as Novartis, Kos Pharmaceuticals,
Organon Biosciences, Pfizer, and JP Morgan Chase. Mr. Pine has a BS
in Consumer Economics from Cornell University and an MBA
from Columbia Business School.
Ken d’Entremont, Chief Executive Officer of
Medexus, commented, “We are pleased to welcome Michael to the team.
Michael has extensive experience in business development and brings
a successful track record of expanding product lines. Having such
an experienced pharmaceutical industry professional and business
leader on board will assist us in identifying in-licensing
opportunities and acquisitions of new complementary assets that can
leverage our North American sales force. Michael can make an
immediate contribution to the numerous deals we are currently
negotiating and will help accelerate our M&A and licensing
strategy to grow revenue, increase cash flow and drive economies of
scale.”
About MedexusMedexus is a
leading specialty pharmaceutical company with a strong North
American commercial platform. The Company’s vision is to provide
the best healthcare products to healthcare professionals and
patients, through our core values of Quality, Innovation, Customer
Service and Teamwork. Medexus Pharmaceuticals is focused on the
therapeutic areas of auto-immune disease, hematology and allergy.
The Company’s leading products are: Rasuvo™ and Metoject®, a unique
formulation of methotrexate (auto-pen and pre-filled syringe)
designed to treat rheumatoid arthritis and other auto-immune
diseases; IXINITY®, an intravenous recombinant factor IX
therapeutic for use in patients 12 years of age or older with
Hemophilia B – a hereditary bleeding disorder characterized by a
deficiency of clotting factor IX in the blood, which is necessary
to control bleeding; and Rupall®, an innovative allergy medication
with a unique mode of action.
For more information, please
contact:
Ken d’Entremont, Chief Executive OfficerMedexus Pharmaceuticals
Inc.Tel.: 905-676-0003E-mail: ken.dentremont@medexus.com
Roland Boivin, Chief Financial OfficerMedexus Pharmaceuticals
Inc.Tel.: 514-762-2626 ext.
202E-mail: roland.boivin@medexus.com
Investor Relations (U.S.):Crescendo Communications, LLCTel:
+1-212-671-1020Email: mdp@crescendo-ir.com
Investor Relations (Canada):Tina ByersAdelaide Capital Tel:
905-330-3275E-mail: tina@adcap.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
READER ADVISORIES
Forward Looking Statements
Certain statements made in this press release
contain forward-looking information within the meaning of
applicable securities laws (“forward-looking
statements”). The words “anticipates”, “believes”,
“expects”, “will”, “plans” and similar expressions are often
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Specific forward-looking statements contained in this news release
include, but are not limited to, statements with respect to the
identification, execution and results of potential M&A and
other growth opportunities. These statements are based on factors
or assumptions that were applied in drawing a conclusion or making
a forecast or projection, including assumptions based on historical
trends, current conditions and expected future developments. Since
forward-looking statements relate to future events and conditions,
by their very nature they require making assumptions and involve
inherent risks and uncertainties. The Company cautions that
although it is believed that the assumptions are reasonable in the
circumstances, these risks and uncertainties give rise to the
possibility that actual results may differ materially from the
expectations set out in the forward-looking statements. Material
risk factors include those set out in the Company's most recent
MD&A; future capital requirements and dilution; intellectual
property protection and infringement risks; competition (including
potential for generic competition); reliance on key management
personnel; the Company’s ability to implement its business plan;
the Company’s ability to leverage its United States and Canadian
infrastructure to promote additional growth, including with respect
to the infrastructure of Medexus Inc. and Medac Pharma, Inc. and
the potential benefits the Company expects to derive therefrom;,
regulatory approval by the Canadian health authorities; product
reimbursement by third party payers; patent litigation or patent
expiry; litigation risk; stock price volatility; government
regulation; and potential third party claims. Given these risks,
undue reliance should not be placed on these forward-looking
statements, which apply only as of the date hereof. Other than as
specifically required by law, the Company undertakes no obligation
to update any forward-looking statements to reflect new
information, subsequent or otherwise.
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jul 2023 to Jul 2024